Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant [clinicaltrials:NCT00068718]

Bio2RDF uri

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant [clinicaltrials:NCT00068718]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00068718

Bio2RDF identifier

NCT00068718

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00068718

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

This phase I/II trial s ...... ematopoietic cell transplant.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Donor Lymphocyte Infusion in T ...... Hematopoietic Cell Transplant

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Safety of DLI following a non-myeloablative transplant, defined as incidence of grade IV acute GVHD Up to 1 year [clinicaltrials_resource:98b1bbd79d07544829b2d777ea1423a5]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Safety of DLI following a non-myeloablative transplant, defined as incidence of grade IV acute GVHD Up to 1 year [clinicaltrials_resource:5e6ba4de93ddb8ddf1157cbe70cbb773]

Safety of DLI following a non-myeloablative transplant, defined as incidence of grade IV acute GVHD Up to 1 year [clinicaltrials_resource:684dacc74bf72898226f7c161445e452]

Safety of DLI following a non-myeloablative transplant, defined as incidence of grade IV acute GVHD Up to 1 year [clinicaltrials_resource:b358b3d64d6e48ed2dbce8d1130de095]

Safety of DLI following a non-myeloablative transplant, defined as incidence of grade IV acute GVHD Up to 1 year [clinicaltrials_resource:b500edbeced4536afa00a003bf3ccdbf]

Safety of DLI following a non-myeloablative transplant, defined as incidence of grade IV acute GVHD Up to 1 year [clinicaltrials_resource:d4d75ce88abe921519af621183c16bc7]

Safety of DLI following a non-myeloablative transplant, defined as incidence of grade IV acute GVHD Up to 1 year [clinicaltrials_resource:dfbb84d95d9acd19fbf095e7878adc50]

collaborator [clinicaltrials_vocabulary:collaborator]

Fred Hutchinson Cancer Research Center [clinicaltrials_resource:0413b67bb11aa7435c2cb6e1a4385dec]

condition [clinicaltrials_vocabulary:condition]

Recurrent Non-Hodgkin Lymphoma [clinicaltrials_resource:29e1724ebd788bf4fdf9ddbeb28c328f]

Recurrent Adult Acute Lymphoblastic Leukemia [clinicaltrials_resource:5386073c17469d430da8f5c53405026c]

Recurrent Adult Acute Myeloid Leukemia [clinicaltrials_resource:75d676c550144f5742d8c7bef77ecb2c]

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive [clinicaltrials_resource:813f79d459a8717de8b6d8e8e0ed2f01]

Recurrent Hodgkin Lymphoma [clinicaltrials_resource:86c38c39793bc54cb1e1cdecb8de2a33]

Recurrent Plasma Cell Myeloma [clinicaltrials_resource:c221f5783fc87e3526fc76506eb4dc67]

condition browse [clinicaltrials_vocabulary:condition-browse]

Hodgkin Disease [clinicaltrials_resource:1d836c68c4cdb16b25ba4d0e6c1d8f4d]

Leukemia, Myeloid [clinicaltrials_resource:34f22f570aedc5ec3cb0f962962465e9]

Blast Crisis [clinicaltrials_resource:39d813e361926233127355f034fc8d1f]

Lymphoma [clinicaltrials_resource:5feaaed5db0085c2b0579d98d486e681]

Leukemia, Myelogenous, Chronic, BCR-ABL Positive [clinicaltrials_resource:65b591b84e48bdce5f65d37c0dbec1f5]

Leukemia [clinicaltrials_resource:78bcaa40f3ac1db6eabd01eea212403c]

Neoplasms, Plasma Cell [clinicaltrials_resource:aa41b92d39b7feaa4386ec3c5f5bf8bf]

Multiple Myeloma [clinicaltrials_resource:b494bb98e15106ec59d72f9432b560bf]

Leukemia, Myeloid, Acute [clinicaltrials_resource:c2a007da2fd0ec6c21bcc10edfde11ce]

Lymphoma, Non-Hodgkin [clinicaltrials_resource:e1643019069c027999cfb69b90f55ab7]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Hodgkin Disease [clinicaltrials_resource:1d836c68c4cdb16b25ba4d0e6c1d8f4d]

Leukemia, Myeloid [clinicaltrials_resource:34f22f570aedc5ec3cb0f962962465e9]

Blast Crisis [clinicaltrials_resource:39d813e361926233127355f034fc8d1f]

Lymphoma [clinicaltrials_resource:5feaaed5db0085c2b0579d98d486e681]

Leukemia, Myelogenous, Chronic, BCR-ABL Positive [clinicaltrials_resource:65b591b84e48bdce5f65d37c0dbec1f5]

Leukemia [clinicaltrials_resource:78bcaa40f3ac1db6eabd01eea212403c]

Neoplasms, Plasma Cell [clinicaltrials_resource:aa41b92d39b7feaa4386ec3c5f5bf8bf]

Multiple Myeloma [clinicaltrials_resource:b494bb98e15106ec59d72f9432b560bf]

Leukemia, Myeloid, Acute [clinicaltrials_resource:c2a007da2fd0ec6c21bcc10edfde11ce]

Lymphoma, Non-Hodgkin [clinicaltrials_resource:e1643019069c027999cfb69b90f55ab7]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

detailed description [clinicaltrials_vocabulary:detailed-description]

PRIMARY OBJECTIVES: ...... are followed up periodically.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00068718 [clinicaltrials_resource:21cef87bb60aa866f8252b4c0ca0287c]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2003-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Therapeutic Allogeneic Lymphocytes [clinicaltrials_resource:92f31fcdf53593846c070673e06f12e0]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Fred Hutchinson Cancer Research Center [clinicaltrials_resource:0413b67bb11aa7435c2cb6e1a4385dec]

location [clinicaltrials_vocabulary:location]

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium [clinicaltrials_resource:f4361c6080bdad8b2902948bd52befed]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00068718

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Donor Lymphocyte Infusion for ...... tioning - A Multi-center Trial

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

1.803e+3

http://www.w3.org/2001/XMLSchema#float

overall official [clinicaltrials_vocabulary:overall-official]

Brenda Sandmaier [clinicaltrials_resource:af023ee351f81c7bcf613f243f3fb9a7]

overall status [clinicaltrials_vocabulary:overall-status]

Active, not recruiting [clinicaltrials_resource:a6bc1606956390bcd6a391faced78809]

oversight [clinicaltrials_vocabulary:oversight]

United States: Federal Government [clinicaltrials_resource:3e6fb85f74da576ef06d30c2ff29436f]

phase [clinicaltrials_vocabulary:phase]

Phase 1/Phase 2 [clinicaltrials_resource:72d8d9eabd48f679d5dffa41c4dd93f7]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

NCI-2010-00163

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Fred Hutchinson Cancer Research Center [clinicaltrials_resource:0413b67bb11aa7435c2cb6e1a4385dec]

start date [clinicaltrials_vocabulary:start-date]

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00068718 study design [clinicaltrials_resource:305ec01d4368c0ea7d265d73112d38d9]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00068718

verification date [clinicaltrials_vocabulary:verification-date]

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00068718

http://www.w3.org/2001/XMLSchema#string

title

Donor Lymphocyte Infusion in T ...... Hematopoietic Cell Transplant

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Donor Lymphocyte Infusion in T ...... t [clinicaltrials:NCT00068718]

@en